Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Beauty Tech Group eyes £320m valuation in London IPO

(Sharecast News) - The Beauty Tech Group expects to be valued at up to £320m when it debuts on the London market, the British skincare specialist confirmed on Wednesday. The firm - known for its LED face masks and at-home laser treatments - said its price range had been set at between 251p and 291p per share, implying a market capitalisation of between £280m and £320m.

It is seeking to raise primary capital of up to £29m through the initially public offering, which is set to launch next month.

LED face masks have surged in popularity recently, supported by celebrity fans such as Serena Williams and considerable social media hype.

The Cheshire-based group, which owns CurrentBody Skin, ZIIP Beauty and Tria Laser, said the IPO would position it for its next stage of development.

The debut should also prove a boost for the London stock market, which has struggled to attract new listings amid strong competition from New York and elsewhere.

Russ Mould, investment director at AJ Bell, said: "It's good to see more companies head to the UK stock market, but a company of this size is going to fly under the radar of most investors.

"We are in an environment where small cap companies are struggling to get investors' attention unless they have a compelling narrative or tap into the hottest investment trends, [such as] AI.

"LED face masks...[are] the talk of the town on social media. But [it's] a competitive industry well served by big players. Beauty Tech will have to work hard to explain why its products are better than others, and how it is able to grow market share quickly."

The Beauty Tech Group is owned by its management team, including co-founders Laurence Newman, chief executive, and chief technology officer Andrew Showman.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.